World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
62444
World Ranking
7798
National Ranking
764

Overview

Keith M. Kerr is affiliated with Aberdeen Royal Infirmary in the United Kingdom. Their work primarily focuses on medicine, with a strong emphasis on pulmonary and respiratory medicine, oncology, and cancer research. Additional areas of study include radiology, nuclear medicine and imaging, as well as molecular biology.

The scientist's research covers a range of topics including lung cancer treatments and mutations, lung cancer diagnosis and treatment, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, radiomics and machine learning in medical imaging, lung cancer research studies, and RNA modifications and cancer.

Keith M. Kerr has contributed extensively to peer-reviewed literature, with notable publications in prominent venues such as the Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology, Journal of Clinical Oncology, and Nature. The number of publications is particularly high in the Journal of Thoracic Oncology, with 21 articles, followed by 8 in Lung Cancer and 7 each in Annals of Oncology and Journal of Clinical Oncology, as well as 6 in Nature.

Recent significant papers authored or co-authored by Keith M. Kerr include:

  • PD-L1 as a biomarker of response to immune-checkpoint inhibitors, 2021, Nature Reviews Clinical Oncology
  • The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015, 2021, Journal of Thoracic Oncology
  • Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Lung adenocarcinoma promotion by air pollutants, 2023, Nature
  • A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee, 2020, Journal of Thoracic Oncology

Frequent collaborators include Yasushi Yatabe, Fred R. Hirsch, Andrew G. Nicholson, William D. Travis, and Ming-Sound Tsao. These co-authors have contributed to multiple joint publications, reflecting collaborative efforts in specialized research areas related to lung cancer and pathology.

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

    William D. Travis;Elisabeth Brambilla;Andrew G. Nicholson;Yasushi Yatabe

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

    S Novello;F Barlesi;R Califano;R Califano;T Cufer

  • Tracking the Evolution of Non–Small-Cell Lung Cancer

    Mariam Jamal-Hanjani;Gareth A. Wilson;Nicholas McGranahan;Nicolai Juul Birkbak

  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. B. A. G. Haanen;F. Carbonnel;C. Robert;K. M. Kerr

  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

    Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani

  • Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim

  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

    Neal I. Lindeman;Philip T. Cagle;Dara L. Aisner;Maria E. Arcila

  • PD-L1 as a biomarker of response to immune-checkpoint inhibitors

    Deborah Blythe Doroshow;Sheena Bhalla;Mary Beth Beasley;Lynette M. Sholl

  • Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

    Nicholas McGranahan;Rachel Rosenthal;Crispin T. Hiley;Crispin T. Hiley;Andrew J. Rowan

  • PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

    Fred R. Hirsch;Abigail McElhinny;Dave Stanforth;James Ranger-Moore

  • Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Reck;S Popat;N Reinmuth;Dirk De Ruysscher

  • The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015.

    Andrew G. Nicholson;Ming S. Tsao;Mary Beth Beasley;Alain C. Borczuk

  • PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

    Ming Sound Tsao;Keith M. Kerr;Mark Kockx;Mary Beth Beasley

  • Guidelines on the radical management of patients with lung cancer

    Eric Lim;David Baldwin;Michael Beckles;John Duffy

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification

    William D. Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G. Nicholson

  • Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

    D. Ross Camidge;Robert C. Doebele;Keith M. Kerr

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

Frequent Co-Authors

Lukas Bubendorf
Lukas Bubendorf University Hospital of Basel
Andrew G. Nicholson
Andrew G. Nicholson Royal Brompton Hospital
Yasushi Yatabe
Yasushi Yatabe Nagoya University
Solange Peters
Solange Peters University Hospital of Lausanne
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Rolf A. Stahel
Rolf A. Stahel University of Zurich
Fiona H Blackhall
Fiona H Blackhall University of Manchester
William D. Travis
William D. Travis Memorial Sloan Kettering Cancer Center
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Sylvie Lantuejoul
Sylvie Lantuejoul Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are exploring options beyond traditional medical school, several online degrees can lead to rewarding careers in healthcare. For those interested in mental health, consider advancing your nursing credentials with an msn to pmhnp online program, which prepares you for specialized roles as a Psychiatric Mental Health Nurse Practitioner.

Administrative careers in health services are also in high demand. You can earn your master’s degree through some of the best online mha programs, gaining leadership and management skills without leaving your job. If cost is a concern, there are many options for the masters in healthcare administration cost that keep expenses reasonable.

For nurses aspiring to reach the highest level of clinical practice, pursuing the cheapest dnp online can be a cost-effective way to earn a Doctor of Nursing Practice. These pathways offer flexibility, affordability, and a direct route to impactful healthcare careers.

Best Scientists Citing Keith M. Kerr

Trending Scientists

Recently Published Articles